You might think pushing blood pressure treatment too hard does more harm than good. But new research from Mass General Brigham scientists, published in the Annals of Internal Medicine, flips that idea on its head—for people at high heart risk, anyway.
Doctors have debated this for years: Is it worth aiming for a systolic blood pressure under 120 mmHg, or should we settle for higher targets?
Three Targets Reveal the Real Impact of Aggressive Treatment
Researchers compared three systolic targets: under 120, 130, or 140 mmHg. They crunched data from the massive SPRINT trial, NHANES survey, and other studies using a computer model to simulate lifelong patient outcomes—not just short-term numbers, but real risks of heart attacks, strokes, and heart failure.
The big takeaway? Even factoring in real-world measurement errors—like stress or “white coat” spikes—the strictest target (under 120) slashed cardiovascular events the most. Intensive treatment projected fewer heart problems compared to moderate goals.
More Meds and Visits Mean More Side Effects—and Costs
Pushing lower often requires more drugs, higher doses, or combos. That ups the odds of side effects like falls, kidney strain, hypotension, or slow heart rate. Healthcare costs climb too, with extra meds and checkups.
Still, it proved cost-effective: One extra quality-adjusted life year costs about $42,000—well within what’s considered a good deal in health economics.
Fewer Heart Attacks and Strokes—Even in the Real World
Bottom line: Benefits beat the risks. The under-120 target cut heart attacks, strokes, and heart failure more than looser ones. And the model baked in everyday messiness—fluctuations from fatigue, office stress, you name it. The edge held up.
“This study should give patients at high cardiovascular risk and their clinicians more confidence in pursuing an intensive blood pressure goal,” said lead author Karen Smith of Brigham and Women’s Hospital.
Not for Everyone—Talk to Your Doctor
These are population-level findings, not a one-size-fits-all rule.
“Our results examine the cost-effectiveness of intensive treatment at the population level. However, given the additional risk of adverse events related to antihypertensives, intensive treatment will not be optimal for all patients,” Smith explained.
Tailor it to your health, risks, and preferences—don’t chase 120 mmHg without guidance, especially if you have high blood pressure.
